SCHEMBL3364790

SCHEMBL3364790

Clc1ccc(-c2cccc3cn(Cc4ccccc4)nc23)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.50
CXCR2 P25025 4/20 0.45
CRHR1 P34998 6/20 0.44
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
MARS1 P56192 1/20 0.42
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
DPP4 P27487 1/20 0.40
KCNH2 Q12809 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40
CNR1 P21554 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3364681 0.90 PARP1 (0.50) PARP1CXCR2CRHR1MARS1CNR1
SCHEMBL3364024 0.84 CRHR1 (0.49) CRHR1
SCHEMBL3367655 0.82 MARS1 (0.44) PARP1CRHR1MARS1CNR1
SCHEMBL3361832 0.77 CRHR1 (0.52) CRHR1KCNH2
Hydrochloric Acid SCHEMBL3364528 0.76 CRHR1 (0.51) CRHR1KCNH2
SCHEMBL3364716 0.75 CNR1 (0.46) CRHR1ALDH1A1DPP4DPP8DPP9
SCHEMBL30995423 0.72 TDP1 (0.45) PARP1ALDH1A1GAAADORA3ADORA2A
SCHEMBL4662108 0.69 CRHR1 (0.50) CRHR1ALDH1A1GAAHPGDDPP4
SCHEMBL10085614 0.68 PARP1 (0.66) PARP1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL18434779 0.67 CRHR1 (0.54) CRHR1ALDH1A1GAACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656353-B1 GABANERGIC MODULATORS HOFFMANN LA ROCHE (CH) 2010-01-27 EP claimed
EP-1656353-B1 GABANERGIC MODULATORS HOFFMANN LA ROCHE (CH) 2010-01-27 EP disclosed
US-7365211-B2 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC (US) 2008-04-29 US disclosed
US-7365211-B2 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC (US) 2008-04-29 US disclosed
US-7365211-B2 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC (US) 2008-04-29 US disclosed
US-20050101614-A1 For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain ROCHE PALO ALTO LLC 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101614-A1 For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain HTR2C, GABRA2, GABRA4 PARP1 3305/4885CXCR2 849/4885CRHR1 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.